“…Reducing hnRNPA2/B1 can inhibit the proliferation of cervical cancer cells and increase their sensitivity to irinotican combined with loplatin chemotherapy (Shi et al, 2018). In addition, hnRNPA2/B1 is involved in the development of nasopharyngeal (Zhang & Li, 2019), esophageal (Zhang & Li, 2019), prostate (Yang et al, 2018), colon (Wu et al, 2019), kidney (Wu et al, 2005), ovarian (Lee et al, 2010), and cervical cancers (Orru, Cunniffe, Ryan, & Schwartz, 2012) and melanoma (Suzuki et al, 2010).…”